GlassScriptPhysician profile
Kirby L Knuth
NPI 1649750126
$1,612.97
in general payments reported to CMS, 2019-2025
22 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.12 · 2022: $224 · 2023: $402 · 2024: $539 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $374.10 | 2022-2025 | Farxiga, Brilinta, Andexxa |
| Amgen INC. | $251.57 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $156.57 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.55 | 2021-2025 | Jardiance |
| Pfizer INC. | $124.48 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $90.25 | 2021-2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $72.13 | 2022-2023 | Verquvo |
| Organogenesis INC. | $42.33 | 2025 | Puraply Wound Matrix |
| Abiomed | $37.94 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $37.24 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $34.99 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.51 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $28.92 | 2021-2023 | Xarelto |
| Scpharmaceuticals INC. | $28.32 | 2023-2024 | |
| Polynovo North America LLC | $23.11 | 2025 | Novosorb Btm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $21.57 | 2024 | Arcalyst |
| Lemaitre Vascular, INC. | $19.71 | 2022 | |
| Genzyme Corporation | $19.64 | 2024 | |
| Impulse Dynamics (USA) INC. | $19.52 | 2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $19.51 | 2024 | |
| Bard Peripheral Vascular, INC. | $18.18 | 2024 | Rotarexs 6 F X 135 Cm |
| Philips North America LLC | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirby Knuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.